Showing 1-10 of 14 "Digestive System Diseases"

Status: Open Not Enrolling

Investigator: Eric Bernicker

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some o ... Read more >

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

Study D5553C0003 is a 28-week, randomized, double-blind, active-controlled, multicenter, Phase 3 efficacy and safety study with a 24-week extension phase of simultaneous administration of exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg ... Read more >

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placeb ... Read more >

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placeb ... Read more >

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with T2DM and to compare outcomes against placebo, on a backg ... Read more >

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies. ... Read more >

Status: Open Not Enrolling

Investigator: David Victor

Study Coordinator: Susan Dorman

Phone: 713.441.6316

The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant. ... Read more >

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to assess the effect of canagliflozin compared to placebo on progression of albuminuria in participants with Type 2 Diabetes Mellitus receiving standard care but with inadequate glycemic control and at elevated risk ... Read more >

Status: Enrolling

Investigator: David Victor

Study Coordinator: Susan Dorman

Phone: 713.441.6316

The purpose of this study is to determine whether ornithine phenylacetate can speed recovery from an acute hepatic encephalopathy episode requiring hospitalization in cirrhotic pa ... Read more >

Status: Enrolling

Investigator: Daniel Lehane

Study Coordinator: Pej Hemati

Phone: 713.441.3926

This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for ap ... Read more >

Status: Enrolling

Investigator: David Victor

Study Coordinator: Alejandro De La Torre

Phone: 000.000.0000

This registry will remain open for approximately 5 years. Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry. When laboratory tests and clinical assessments ... Read more >

Status: Enrolling

Investigator: Sherilyn Gordon Burroughs

Study Coordinator: Joel Cisneros

Phone: 713.441.6311

The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) through at least Study Day 91. The secondary o ... Read more >

Status: Enrolling

Investigator: Eric Bernicker

Study Coordinator: Allison Rounds

Phone: 713.441.8389

The purpose of this study is to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer. ... Read more >

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events). Examples of major cardiovasc ... Read more >